#Ireland #Galway #Neurent Medical #NEUROMARK #Chronic Rhinitis

Neurent Medical Reveals Positive Outcomes from NEUROMARK® Clinical Trial

Neurent Medical, renowned for its innovation in non-surgical therapies for chronic rhinitis, has recently released groundbreaking findings from its randomized controlled trial assessing the NEUROMARK® System. This publication, recognized in the International Forum of Allergy & Rhinology, highlights the device's efficacy in providing relief from chronic nasal symptoms, offering patients a new ray of hope.

The NEUROMARK System utilizes impedance-controlled radiofrequency ablation targeted at the posterior nasal nerve region. This innovative approach aims to treat chronic rhinitis by addressing the underlying neural causes of nasal discomfort rather than merely symptom management. Results showed a notable superiority of NEUROMARK treatment over sham control, leading to significant enhancements in nasal symptoms and overall quality of life measures.

Conducted across multiple centers with a total of 132 participants, the trial allotted individuals to either receive active treatment or a sham control. At the 90-day mark, the primary endpoint, represented by the reflective Total Nasal Symptom Score (rTNSS), demonstrated that a substantial 73.3% of those treated with NEUROMARK reported improvement, contrasting sharply with only 35.0% of participants in the control group (p < 0.001).

Key Findings from the Study

Beyond the primary endpoint, the study yielded significant secondary outcomes. Participants treated with the NEUROMARK System showcased impressive decreases in symptoms of postnasal drip, chronic cough, and nasal obstruction. They also reported better overall well-being through assessments via the mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) and the Patient Health Questionnaire-9 (PHQ-9).

The responder rates in both the NOSE (Nasal Obstruction Symptom Evaluation) and mini-RQLQ assessments were markedly higher in the active treatment group compared to those receiving placebo treatment. These findings raise hopes for those struggling with persistent nasal symptoms and signify a considerable leap forward in chronic rhinitis management options.

Dr. Mas Takashima, the Principal Investigator of the trial, emphasized the implication of these results, stating, “Our findings present high-quality clinical evidence that supports posterior nasal nerve ablation as an effective treatment for chronic rhinitis. The marked improvements observed can significantly influence the lives of patients whose symptoms continue despite conventional medical therapies.”

Brian Shields, CEO of Neurent Medical, echoed this sentiment, expressing pride in the company's commitment to evidence-backed innovation. He noted, “The success of this randomized controlled trial signifies an essential milestone for us, underpinning the clinical significance of the NEUROMARK System and the potential for its widespread adoption among patients suffering from chronic rhinitis.”

Looking Ahead

As chronic rhinitis affects millions globally, the positive outcomes from the NEUROMARK trial can pave the way for further research into minimally invasive solutions for various nasal disorders. With its ability to deliver targeted therapy with fewer side effects than traditional approaches, the NEUROMARK System embodies a transformative option, highlighting a future where patients can embrace life free of debilitating nasal symptoms.

For more details about the NEUROMARK System and its transformative potential, visit www.neuromark.com.